Protalix BioTherapeutics Inc (PLX)

1.23 0.00 (0.00%) USD  |  NYAM  |  Aug 18, 16:00
1.22 -0.01 (-0.81%) After-Hours: 20:00
More

Protalix BioTherapeutics News

News

Headline
Wire
Time (ET)
PLX: Eyes on Upcoming BLA Resubmission
Yahoo
08/16 05:55
Protalix BioTherapeutics GAAP EPS of -$0.11 beats by $0.07, revenue of $8.75M beats by $6.08M
SA Breaking News
08/15 06:52
Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results
PR Newswire
08/15 06:50
Notable earnings before Monday's open
SA Breaking News
08/12 10:53
Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022
PR Newswire
08/08 06:50
Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors
PR Newswire
06/30 16:30
10 Popular Penny Stocks on Robinhood
Yahoo
06/14 09:23
Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease
PR Newswire
05/26 16:30
-- Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS Reports Q1 Revenue $16.1M
MT Newswires
05/16 06:50
Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results
PR Newswire
05/16 06:50
Notable earnings before Monday's open
SA Breaking News
05/13 10:29
Protalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022
PR Newswire
05/09 06:50
Sector Update: Health Care Stocks Struggle in Weakening Thursday Markets
MT Newswires
04/21 15:16
Sector Update: Health Care Stocks Underwater in Thursday Trading
MT Newswires
04/21 12:56
Protalix BioTherapeutics Files $100 Million Mixed Shelf
MT Newswires
04/21 03:07
Thinking about buying stock in ENDRA Life Sciences, SeaChange, Protalix Biotherapeutics, Dingdong, or BigBear.ai?
PR Newswire
04/08 09:31
BTTX, ATER and LGHL among pre market gainers
SA Breaking News
04/08 08:44
Protalix BioTherapeutics Says Phase 3 Trial of Fabry Disease Treatment Met Primary Endpoint; Shares Surge
MT Newswires
04/04 14:00
Top Midday Gainers
MT Newswires
04/04 13:07
Protalix, Biophytis top healthcare gainers; while Curis, Longeveron lead losers' pack
SA Breaking News
04/04 10:02
Wall Street Treads Water Pre-Bell, Twitter Rally Underpins Sentiment
MT Newswires
04/04 09:20
Protalix stock soars 33% as PRX–102 for Fabry disease equals Sanofi's Fabrazyme in trial
SA Breaking News
04/04 08:06
Top Premarket Gainers
MT Newswires
04/04 08:05
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
PR Newswire
04/04 06:50
Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results
PR Newswire
03/31 06:50
Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022
PR Newswire
03/24 06:50
Protalix, Chiesi report final data from late-stage study of PRX‑102 for Fabry disease
SA Breaking News
03/18 07:46
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease
PR Newswire
03/18 06:50
Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022
PR Newswire
02/03 06:50
Protalix BioTherapeutics Issues 2021 Letter to Stockholders
PR Newswire
12/22 06:50
-- Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS Reports Q3 Revenue $12.1M, vs. Street Est of $6.9M
MT Newswires
11/15 06:51
Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update
PR Newswire
11/15 06:50
Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021
PR Newswire
11/08 06:50
Protalix BioTherapeutics, Chiesi Global Close Final Dosing of Last Patient in Phase III Clinical Trial of PRX-102 for Fabry Disease
MT Newswires
10/15 09:33
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease
PR Newswire
10/15 08:37
APRN, CEI and GOTU among mid-day movers
SA Breaking News
10/11 12:39
Protalix, Chiesi Say PRX-102 Fabry Disease Treatment Got FDA Document Indicating Pathway For Resubmission of License Application
MT Newswires
10/11 11:42
Protagonist Therapeutics, Adamas Pharmaceuticals leads healthcare gainers; Voyager Therapeutics, Protalix BioTherapeutics among major losers
SA Breaking News
10/11 11:01
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease
PR Newswire
10/11 06:50
Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update
PR Newswire
08/16 06:50
Protalix BioTherapeutics Announces Private Note Exchange
PR Newswire
08/13 06:50
Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021
PR Newswire
08/09 07:15
Protalix Bio submits Type A meeting request to FDA for PRX-102 in Fabry disease
SA Breaking News
08/02 07:07
Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA
PR Newswire
08/02 06:50
Protalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021
PR Newswire
06/28 06:50
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
Globe Newswire
06/07 22:17
Ra Medical Systems, Sundial Growers leads healthcare gainers; PetMed Express, SELLAS Life Sciences among major losers
SA Breaking News
06/03 11:07
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
PR Newswire
06/03 00:30
BriaCell Therapeutics, Constellation Pharmaceuticals leads healthcare gainers; iRhythm Technologies, Progenity among major losers
SA Breaking News
06/02 11:02
MorphoSys, iRhythm Technologies among major healthcare premarket losers' pack
SA Breaking News
06/02 08:14
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease
PR Newswire
06/02 06:50
Protalix swings to Q1 net loss, but beats on EPS and revenue estimates
SA Breaking News
05/14 09:29
Protalix BioTherapeutics EPS beats by $0.03, beats on revenue
SA Breaking News
05/14 06:51
Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update
PR Newswire
05/14 06:50
Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021
PR Newswire
05/07 10:30
Thinking about buying stock in Ashford Hospitality Trust, Vaxart, Ocugen, Viracta Therapeutics, or Protalix Biotherapeutics?
PR Newswire
05/03 08:30
--HC Wainwright Adjusts Price Target on Protalix BioTherapeutics to $7 From $11, Maintains Buy Rating
MT Newswires
05/03 07:18
Sector Update: Health Care Stocks Improve This Afternoon But Can't Completely Shake Wednesday Declines
MT Newswires
04/28 15:50
Protalix Says US FDA Seeks Israeli Manufacturing Facility Inspection Regarding PRX-102 Biologics License Application; Shares Slump
MT Newswires
04/28 14:46
Protalix Bio says FDA rejection of PRX–102 was not due to safety/ efficacy issues
SA Breaking News
04/28 14:29
Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA
PR Newswire
04/28 13:27
Sector Update: Health Care Stocks Losing Ground Wednesday
MT Newswires
04/28 13:00
ADMA Biologics, Brooklyn ImmunoTherapeutics leads healthcare gainers; Protalix BioTherapeutics, Benitec Biopharma among major losers
SA Breaking News
04/28 11:01
Spotify Technology, Pinterest among premarket losers' pack
SA Breaking News
04/28 08:26
Protalix Bio slides on FDA rejection of experimental therapy for Fabry disease
SA Breaking News
04/28 06:49
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
PR Newswire
04/28 01:50
Seeking Alpha Catalyst Watch
SA Breaking News
04/23 15:30
Protalix BioTherapeutics stock up after FY revenue beat
SA Breaking News
03/30 08:18
Protalix BioTherapeutics EPS beats by $0.12, beats on revenue
SA Breaking News
03/30 07:00
Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results
PR Newswire
03/30 06:50
Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021
PR Newswire
03/22 06:50
Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
PR Newswire
03/04 06:50
Thinking about buying stock in Vascular Biogenics, Oncolytics Biotech, Protalix Biotherapeutics, AMC Entertainment, or Applied DNA Sciences?
PR Newswire
02/23 08:30
VET, TCOM, TTM and ZI among premarket gainers
SA Breaking News
02/23 08:18
Protalix Bio up 6% on positive PRX–102 data in Fabry disease
SA Breaking News
02/23 07:36
Protalix BioTherapeutics, Chiesi Global Rare Diseases Provide Positive Update on Fabry Disease Drug Candidate
MT Newswires
02/23 07:17
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
PR Newswire
02/23 06:50
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
PR Newswire
02/18 08:02
FOLD, SPCE among premarket losers
SA Breaking News
02/12 08:26
Protalix Bio plummets 17% on capital raise
SA Breaking News
02/12 05:31
Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common Stock
PR Newswire
02/11 21:16
Protalix BioTherapeutics Plans 6.5 Million Share Offering -- Stock Slides 8.5% After-Hours
MT Newswires
02/11 16:58
Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock
PR Newswire
02/11 16:35
Protalix Bio inks licensing deal for alidornase alfa; shares up 4%
SA Breaking News
02/11 07:26
Protalix BioTherapeutics Enters Global License Agreement With SarcoMed USA
MT Newswires
02/11 07:26
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery
PR Newswire
02/11 06:50
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021
PR Newswire
02/10 07:01
Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021
PR Newswire
02/01 06:50
Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in January
PR Newswire
01/04 06:50
Protalix BioTherapeutics Says Phase III Trial of PRX-102 Showed Improvement in Renal Function
MT Newswires
12/30 10:40
Protalix Biotherapeutics announces final results of BRIDGE phase III open-label switch-over clinical trial
SA Breaking News
12/30 07:02
Protalix BioTherapeutics Issues 2020 Letter to Shareholders
PR Newswire
12/30 06:50
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
PR Newswire
12/30 06:00
FDA Extends Review Date of Protalix BioTherapeutics' Drug Candidate for Fabry Disease
MT Newswires
11/27 07:21
FDA extends Protalix Bio's target action date for PRX–102 application to April 27, 2021
SA Breaking News
11/27 07:16
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
PR Newswire
11/27 06:50
Protalix BioTherapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference
PR Newswire
11/05 06:50
Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30
PR Newswire
10/29 13:33
Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
PR Newswire
10/29 06:50
Protalix BioTherapeutics to Participate in Virtual Investor KOL Roundtable
PR Newswire
10/26 06:50
Seeking Alpha Catalyst Watch
SA Breaking News
10/23 15:30
Protalix BioTherapeutics to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on October 29, 2020
PR Newswire
10/22 06:50
Protalix BioTherapeutics, Chiesi Global Launch Expanded Access Program For Fabry Disease Drug Candidate
MT Newswires
10/02 11:10
Protalix Bio launches expanded access program for pegunigalsidase alfa for Fabry Disease in U.S.
SA Breaking News
10/02 08:47
Protalix BioTherapeutics regains NYSE American compliance
SA Breaking News
09/08 09:28
Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards
PR Newswire
09/08 06:55
Protalix BioTherapeutics to Present in the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
PR Newswire
09/08 06:45
Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the Proposed Treatment of Fabry Disease
PR Newswire
08/24 06:50
Protalix Bio, Chiesi Unit Say US FDA Accepts BLA for Pegunigalsidase Alfa for Treatment of Fabry Disease
MT Newswires
08/11 10:08
NIO, NCLH among premarket gainers
SA Breaking News
08/11 08:25
FDA accepts Protalix application for enzyme replacement therapy for Fabry
SA Breaking News
08/11 07:06
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review
PR Newswire
08/11 06:50
-- Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS INC. Posts Q2 Revenue $10.967M, vs. Street Est of $5.25M
MT Newswires
08/10 06:52
Protalix BioTherapeutics EPS beats by $0.07, beats on revenue
SA Breaking News
08/10 06:52
Protalix BioTherapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
PR Newswire
08/10 06:50
Protalix BioTherapeutics to Present at the BTIG Virtual Biotechnology Conference 2020
PR Newswire
08/06 13:02
Protalix BioTherapeutics to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on August 10, 2020
PR Newswire
08/03 09:13
Protalix BioTherapeutics Enters into Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Diseases
PR Newswire
07/23 14:29
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
PR Newswire
06/08 17:00
--Analyst Actions: HC Wainwright Lifts Price Target on Protalix BioTherapeutics to $11 From $3, Reiterates Buy Rating
MT Newswires
06/08 10:00
Protalix Bio +3% on Q1 results
SA Breaking News
06/01 07:32
-- Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS INC. Posts Q1 Revenue $21.646M
MT Newswires
06/01 07:07
Protalix BioTherapeutics EPS beats by $0.40
SA Breaking News
06/01 06:55
Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update
PR Newswire
06/01 06:50
Israel's Protalix BioTherapeutics Submits License Application to FDA for PRX-102 to Treat Fabry Disease; Stock Up Near 6%
MT Newswires
05/28 13:03
U.S. application filed for Protalix Bio's pegunigalsidase alfa for Fabry
SA Breaking News
05/28 07:51
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
PR Newswire
05/28 06:50
Protalix BioTherapeutics to Hold First Quarter 2020 Financial Results and Business Update Conference Call on June 1, 2020
PR Newswire
05/22 16:05
Sector Update: Large Rise for Health Care Stocks Keeping Nasdaq Composite, S&P 500 on Positive Ground
MT Newswires
05/11 15:53
Protalix BioTherapeutics Jumps as Fabry Disease Phase 3 Trial Delivers 'Positive' Topline Results
MT Newswires
05/11 14:58
CAH, BLUE among premarket gainers
SA Breaking News
05/11 09:26
CAH, BLUE among premarkt gainers
SA Breaking News
05/11 09:26
Protalix Bio's PRX-102 shows positive effect in late-stage Fabry study
SA Breaking News
05/11 08:27
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
PR Newswire
05/11 06:50
Healthcare - Top 5 Gainers / Losers
SA Breaking News
04/30 11:02
Protalix BioTherapeutics Registers Potential Secondary Offering of Common Shares
MT Newswires
04/20 05:28
Protalix BioTherapeutics files to sell 35.21M shares of common stock for holders
SA Breaking News
04/18 03:50
Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement
PR Newswire
03/18 12:12
Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein
PR Newswire
03/16 06:50
Protalix Bio +9% on capital raise
SA Breaking News
03/12 09:33
Protalix BioTherapeutics beats on revenue
SA Breaking News
03/12 08:07
Protalix BioTherapeutics Reports Fourth Quarter and Full Year 2019 Financial and Business Results
PR Newswire
03/12 08:04
Protalix BioTherapeutics Announces $43.7 Million in Financing to Further Advance its Programs in Fabry Disease
PR Newswire
03/12 07:55
Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020
PR Newswire
03/05 07:00
Sector Update: Most Health Care Heavyweights Trade Higher Pre-Market Tuesday
MT Newswires
02/11 09:04
Protalix BioTherapeutics Says Drug Candidate Shows Potential as Treatment for Fabry Disease
MT Newswires
02/11 06:06
Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium™ 2020
PR Newswire
02/10 16:05
Key events next week - healthcare
SA Breaking News
02/07 09:47
Protalix BioTherapeutics, Chiesi Farmaceutici Disclose Agreement for Initial Study into Fabry Disease
MT Newswires
02/06 14:28
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease
PR Newswire
02/06 06:50
Protalix BioTherapeutics to Participate in the 2020 BIO CEO & Investor Conference and the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference
PR Newswire
02/04 09:00
Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium™ 2020
PR Newswire
01/30 07:30
WBA, ITCI among premarket losers
SA Breaking News
01/08 09:14
PLUG, NIO among premarket gainers
SA Breaking News
01/06 09:17
FCEL, PLX, CLB and SAVA among midday movers
SA Breaking News
12/31 12:42
FCEL, MBOT, PLX and TTPH among midday movers
SA Breaking News
12/27 12:41
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
PR Newswire
12/19 06:50
Protalix BioTherapeutics Gets Shareholder Nod for One-for-10 Reverse Stock Split to Regain Listing Compliance; Shares Fall
MT Newswires
12/09 17:11
Protalix to reverse split shares 1:10
SA Breaking News
12/09 16:15
Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split
PR Newswire
12/09 16:05
Protalix BioTherapeutics to Provide Update on Fabry Disease Drug Candidate; Shares Up 5% Pre-Bell
MT Newswires
11/27 09:10
Protalix Bio to host KOL meeting on PRX‑102; shares up 8% premarket
SA Breaking News
11/27 07:30
Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX‑102 Drug Candidate for the Treatment of Fabry Disease
PR Newswire
11/27 06:50
Wall Street Wavers Pre-Bell Despite Positive Trade Signals From China
MT Newswires
11/18 09:11
US Futures Inch Higher on US-China Trade Optimism
MT Newswires
11/18 08:06
Protalix Bio +25% premarket on successfully completing pre-BLA meeting for accelerated approval of PRX‑102
SA Breaking News
11/18 07:05
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
PR Newswire
11/18 06:50
Protalix BioTherapeutics EPS beats by $0.02, misses on revenue
SA Breaking News
11/07 07:07
Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update
PR Newswire
11/07 06:50
Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019
PR Newswire
10/29 07:00
Protalix up 18% premarket on longer-term PRX-102 data
SA Breaking News
10/17 08:28
Protalix BioTherapeutics Phase 3 Study Showed Positive Results of Fabry Disease Treatment
MT Newswires
10/17 08:18
Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease
PR Newswire
10/17 07:40
Protalix, Chiesi Complete Enrollment of Phase 3 Study of Fabry Disease Drug
MT Newswires
09/24 15:37
Protalix completes enrollment in third late-stage study of PRX-102 in Fabry
SA Breaking News
09/24 09:04
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease
PR Newswire
09/24 07:00
Protalix BioTherapeutics Hires Advisory Firm to Evaluate Strategic Options, Shares Down 7%
MT Newswires
08/22 09:40
Protalix Bio to evaluate alternatives to maximize shareholder value
SA Breaking News
08/22 09:17
Protalix BioTherapeutics EPS misses by $0.02
SA Breaking News
08/08 06:12
Protalix BioTherapeutics Names New CFO
MT Newswires
07/29 12:41
New finance chief at Protalix Bio
SA Breaking News
07/29 09:32
Protalix BioTherapeutics Completes Enrollment in Late-Stage Study of Metabolic Disorder Therapeutic
MT Newswires
06/17 09:19
Sector Update: Health Care Stocks Rise, Keeping Pace with Broader Markets
MT Newswires
06/06 16:12
Sector Update: Health Care Stock Mostly Higher in Recent Trade
MT Newswires
06/06 13:35
Sector Update: Health Care Giants Mixed In Thursday's Pre-Market Trading
MT Newswires
06/06 09:07
Protalix BioTherapeutics Surges 24% Pre-Bell; Teams With Chiesi Farmaceutici to File BLA for Fabry Disease Treatment in Q1
MT Newswires
06/06 08:05
Protalix Bio and Chiesi to apply for accelerated approval of pegunigalsidase alfa; shares up 16% premarket
SA Breaking News
06/06 07:30
Protalix BioTherapeutics Names New CEO
MT Newswires
05/21 07:42
Protalix Bio Q1 top line up 55%
SA Breaking News
05/06 07:52
Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update
Globe Newswire
05/06 07:00
Protalix BioTherapeutics to Hold First Quarter 2019 Financial Results and Corporate Update Conference Call on May 6, 2019
Globe Newswire
04/29 07:00
Research Report Identifies TTM Technologies, Zumiez, Global Net Lease, Catabasis Pharmaceuticals, BioPharmX, and Protalix BioTherapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Globe Newswire
04/12 08:10
Protalix files for $100M mixed shelf
SA Breaking News
03/29 17:02
Protalix BioTherapeutics Files for $100 Mln Mixed Shelf
MT Newswires
03/29 16:16
Protalix BioTherapeutics +4% on FY 2018 results
SA Breaking News
03/18 07:33
Protalix BioTherapeutics reports FY results
SA Breaking News
03/18 06:55
Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update
Globe Newswire
03/18 06:50
Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call
Globe Newswire
03/13 17:15
Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019
Globe Newswire
03/06 07:30
Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
Globe Newswire
02/05 07:00
Key events next week - healthcare
SA Breaking News
02/01 09:12
New Research: Key Drivers of Growth for Voya Financial, Conduent, Milacron, Altair Engineering, Genesis Healthcare, and Protalix BioTherapeutics — Factors of Influence, Major Initiatives and Sustained Production
Globe Newswire
01/29 08:15
Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
Globe Newswire
01/28 07:00
Protalix completes enrollment in late-stage study of PRX-102 in Fabry
SA Breaking News
12/17 11:55
Protalix BioTherapeutics Completes Phase 3 Trial Enrollment for Fabry Disease Treatment
MT Newswires
12/17 08:09
Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
Globe Newswire
12/17 07:00
Protalix BioTherapeutics down 4% on Q3 results
SA Breaking News
11/07 08:52
Protalix BioTherapeutics down 4% on Q3 result
SA Breaking News
11/07 08:52
Protalix BioTherapeutics misses by $0.06, misses on revenue
SA Breaking News
11/07 07:01
Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update
Globe Newswire
11/07 07:00
Protalix BioTherapeutics to Hold Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018
Globe Newswire
10/29 07:00
New Research: Key Drivers of Growth for Cenovus Energy, Protalix BioTherapeutics, Rayonier Advanced Materials, B2Gold, Match Group, and Qudian Inc. Sponsored ADR — Factors of Influence, Major Initiatives and Sustained Production
Globe Newswire
10/17 09:25
Wall Street Sees Stumble at Open as Markets Eye China and Italy
MT Newswires
10/08 08:58
Protalix BioTherapeutics Reports Positive Data From PRX-102 Study to Treat Fabry Disease; Shares Up 8% Pre-Bell
MT Newswires
10/05 08:43
Protalix up 4% premarket on additional data on Fabry candidate PRX-102
SA Breaking News
10/05 07:35
Protalix BioTherapeutics Presents Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018
Globe Newswire
10/05 07:00
Key events next week - healthcare
SA Breaking News
09/28 08:57
Close Update: Dow Sets Record High as Trade-Sensitive Industrials Outperform
MT Newswires
09/21 16:34
Mid-Day Update: Dow and S&P 500 Set New Records as Risks of Trade War Wanes, Manufacturing Sector Improves
MT Newswires
09/21 13:19
Protalix up 20% on positive PRX-102 data in Fabry
SA Breaking News
09/21 12:02
Update: Protalix BioTherapeutics Jumps 16% Off Halt, Says Fabry Disesase Treatment Study Data Positive So Far
MT Newswires
09/21 11:47
Protalix BioTherapeutics Due Off Halt at 1110 AM ET, Says Fabry Disesase Treatment Study Data Positive So Far
MT Newswires
09/21 11:12
Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease
Globe Newswire
09/21 10:57
Protalix BioTherapeutics to Present Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018
Globe Newswire
09/17 07:00
Abivax UC candidate shows positive action in mid-stage study
SA Breaking News
09/05 12:17
Protalix BioTherapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
Globe Newswire
08/23 07:00
Research Report Identifies Nomad Foods, AutoNation, Entercom Communications, IMAX, Protalix BioTherapeutics, and Yamana Gold with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Globe Newswire
08/22 07:45
Protalix BioTherapeutics Appoints David Granot to its Board of Directors
Globe Newswire
08/13 07:00
Protalix BioTherapeutics Q2 revenues off 69%
SA Breaking News
08/09 08:20
Protalix BioTherapeutics misses by $0.02, misses on revenue
SA Breaking News
08/09 07:02
Protalix BioTherapeutics Reports 2018 Second Quarter Results and Provides Corporate Update
Globe Newswire
08/09 07:00
Protalix BioTherapeutics to Hold Second Quarter 2018 Financial Results and Corporate Update Conference Call on August 9, 2018
Globe Newswire
07/31 07:00
Protalix BioTherapeutics Soars 18%; Grants Developmental Rights to Chiesi for Up To $1 Bln Milestone Payments
MT Newswires
07/24 13:05
Wall Street Sees Strong Open as Alphabet Earnings Buoy Markets
MT Newswires
07/24 09:21
Protalix out-licenses U.S. rights to PRX-102 for up to $805M; shares up 21% premarket
SA Breaking News
07/24 07:47
Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Globe Newswire
07/24 07:00
Translate Bio prices upsized initial public offering
SA Breaking News
06/27 18:47
Report: Exploring Fundamental Drivers Behind Virtu Financial, Littelfuse, Gogo, Brookfield Asset Management, Protalix BioTherapeutics, and Halozyme Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
Globe Newswire
06/13 08:00
Sector Update: Health Care Stocks Trim Declines
MT Newswires
06/05 16:01
Sector Update: Health Care Stocks Struggling to Find Much Support
MT Newswires
06/05 13:57
Sector Update: Health Care Stocks Lower in Pre-Market; Protalix BioTherapeutics Up on Additional Positive Data From Ulcerative Colitis Trial
MT Newswires
06/05 08:50
Protalix Biotherapeutics announces additional positive results from the phase II clinical trial of OPRX-106 for the treatment of UC
SA Breaking News
06/05 08:20
Sector Update: Health Care
MT Newswires
06/05 08:09
Protalix BioTherapeutics Up Nearly 4% on Additional Positive Results from Final Analysis of Ulcerative Colitis Trial
MT Newswires
06/05 07:40
Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
Globe Newswire
06/05 07:00
Protalix BioTherapeutics Reports Baseline Characteristics of Fabry Disease Patients Screened in Phase III BALANCE Study of Pegunigalsidase Alfa
MT Newswires
05/25 07:55
Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress
Globe Newswire
05/25 07:00
Protalix Announces Exchange and Discharge of Remaining 2018 Notes
Globe Newswire
05/24 07:00
Protalix Q1 revenues up 59%
SA Breaking News
05/09 08:14
Protalix BioTherapeutics beats by $0.03, beats on revenue
SA Breaking News
05/09 07:03